<DOC>
	<DOCNO>NCT00830180</DOCNO>
	<brief_summary>To evaluate safety efficacy anti-NGF AB cancer patient pain due bone metastasis participate double-blind Study A4091003 wish receive open-label therapy .</brief_summary>
	<brief_title>Open Label Extension In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<criteria>Prostate cancer , breast cancer , renal cell carcinoma multiple myeloma diagnose metastasized bone ; Karnofsky Performance Score â‰¥40 % Baseline ; patient randomize treat intravenous study drug doubleblind Study A4091003 . Patient withdrawn Study A4091003 adverse event serious adverse event ; Occurrence adverse event condition Study A4091003 since termination study , opinion Investigator , would put patient increase safety risk exclude subject participate openlabel extension Study A4091029 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>NGF</keyword>
	<keyword>open-label extension</keyword>
</DOC>